Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This prospective chronotherapy trial will investigate the potential differing efficacy of
ramipril in doses from 5 to 10 mg/day when administered, as a monotherapy either upon
awakening from nighttime sleep or at bedtime, to diurnally active patients with grade 1 or 2
essential hypertension, who will be evaluated by 48-hour ABPM before and after pharmacologic
intervention. The benefits from this trial may be extremely important, taking into account
1. the high prevalence of non-dipping among patients with essential hypertension
2. the need for a proper 24-hour BP control with particular emphasis on the regulation of
nighttime resting BP mean
3. the lacking information on the administration-time dependent effects on BP of ramipril,
a widely used ACEI in doses of 5-10 mg/day.
Phase:
Phase 4
Details
Lead Sponsor:
University of Vigo
Collaborator:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer